Novel Agents in the Treatment of Lung Cancer
First Cambridge Conference - October 2003
This program was based on a conference of multidisciplinary leaders in lung cancer research and clinical care. The program developed content for a peer reviewed educational journal publication for medical oncologists and pulmonary specialists who wish to learn more about novel approaches to the treatment of lung cancer..
The program was directed by Thomas J. Lynch, Jr., MD , Chief, Hematology/Oncology, Massachusetts General Hospital Cancer Center.
Educational Objectives
1) Review important aspects of lung cancer biology as they pertain to novel treatments. 2) Discuss the rationale for identifying a target as therapeutically important. 3) Appreciate the role of molecularly targeted agents in the current treatment of advanced lung cancer. 4) Assess the ongoing trials using these agents and the impact that such studies may have on future patient care.
Educational Grant Support
The program was supported by educational grants provided by AstraZeneca Pharmaceuticals, Aventis Pharmaceuticals, Bristol Myers Squibb/ ImClone, Eli Lilly & Co, Genentech BioOncology, and Pfizer Oncology.
Sponsorship
CME sponsorship, program management and editorial assitance were provided by InforMEDical.
The conference proceedings were published as a peer-reviewed CME supplement to Clinical Cancer Research Vol 10. No 12 (Part 2). June 1 2004.
The CME activity based on the publication was effective July 2005 through July 2007.
